Uridine
CAS 58-96-8
Uridine (CAS 58-96-8) is a Phase 3 pharmaceutical compound with 5 bioactivity targets and 10 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | Potency | 61002.615 nM | 7 | - |
| - | IC50 | 21040 nM | 5 | - |
| - | Ki | 23820 nM | 5 | - |
| - | EC50 | 65900 nM | 1 | - |
| - | EC50 | 10 ug.mL-1 | 1 | - |
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| URIDINE | 11017 | SU | MTHSPL |
| uridine | 11017 | IN | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Uridine used for in pharmaceutical contexts?
Uridine (CAS 58-96-8) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Uridine?
Uridine has 10 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Cerebral haematoma, Disorientation, Dizziness, Eye pain, Fatigue. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Uridine also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Uridine with EU status "permitted".
What clinical phase is Uridine in?
Uridine is rendered with ChEMBL max phase 3.